Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.25 Average Price Target from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $35.25.

A number of equities research analysts have recently commented on ANRO shares. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Wolfe Research started coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Wedbush increased their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Bank of America started coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target on the stock.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in the company. Quantinno Capital Management LP grew its holdings in shares of Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after buying an additional 490 shares during the last quarter. Peapod Lane Capital LLC grew its holdings in shares of Alto Neuroscience by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after buying an additional 3,106 shares during the last quarter. Torren Management LLC purchased a new stake in Alto Neuroscience in the fourth quarter worth approximately $62,000. XTX Topco Ltd boosted its holdings in Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after purchasing an additional 6,100 shares during the last quarter.

Alto Neuroscience Price Performance

Shares of ANRO opened at $22.68 on Friday. The stock has a market cap of $795.77 million, a PE ratio of -9.37 and a beta of 1.22. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. Alto Neuroscience has a fifty-two week low of $2.15 and a fifty-two week high of $28.44. The firm’s 50-day simple moving average is $22.71 and its two-hundred day simple moving average is $19.78.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Analysts anticipate that Alto Neuroscience will post -3.01 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.